Loading…
Cross‐resistance to cytosine arabinoside in a multidrug‐resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy
The pyrimidine analogue cytosine arabinoside (AraC) is one of the most effective drugs used in the treatment of acute leukaemia. Overexpression of the multidrug resistance (MDR‐1) gene and its product, P‐glycoprotein (P‐gp), is associated with cellular resistance to drugs, such as anthracyclines and...
Saved in:
Published in: | British journal of haematology 2001-09, Vol.114 (3), p.557-565 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763 |
---|---|
cites | cdi_FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763 |
container_end_page | 565 |
container_issue | 3 |
container_start_page | 557 |
container_title | British journal of haematology |
container_volume | 114 |
creator | Månsson, Emma Paul, Astrid Löfgren, Christina Ullberg, Karin Paul, Christer Eriksson, Staffan Albertioni, Freidoun |
description | The pyrimidine analogue cytosine arabinoside (AraC) is one of the most effective drugs used in the treatment of acute leukaemia. Overexpression of the multidrug resistance (MDR‐1) gene and its product, P‐glycoprotein (P‐gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. This resistance can be reversed by cyclosporine analogues or verapamil (ver). We investigated the in vitro cross‐resistance to AraC in a doxorubicin‐resistant HL60 cell line, with an elevated expression of the MDR‐1 gene. The resistant clone showed an eightfold increased resistance to AraC and a two‐ to fourfold resistance to the other analogues, as measured by cytotoxicity test. There was no significant increase in the activity of 5′‐nucleotidase or in the amount of deoxyribonucleotide pools between cell lines. We could, however, detect a reduction in deoxycytidine kinase (dCK) activity (30%, P = 0·021, using deoxycytidine as substrate) and the level of AraC triphosphates was significantly reduced in the resistant cells (70%, P = 0·009). When the cells were exposed to cyclosporin A (CsA) or the cyclosporine analogue PSC 833 (PSC) in combination with AraC, there was more extensive apoptosis, as measured by formation of oligonucleosomal DNA fragmentation and caspase‐3‐like activity, than with exposure to AraC alone. We also found an increased retention of AraC in the resistant cells when incubated with AraC in combination with CsA. Ver in combination with AraC, failed to increase apoptosis for the resistant cell line. Our data suggests that the resistance to AraC for the P‐gp‐expressing cells is a result of a reduction of dCK activity and an increase in efflux, the latter possibly depending on P‐gp. A combination of CsA or PSC with AraC may improve the effect of AraC in vivo. |
doi_str_mv | 10.1046/j.1365-2141.2001.02979.x |
format | article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_596669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71170126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEotvCKyALIW4JthPbMRKHsioUVIkLnC3HcVgvTrzYibq58Qi8DC_Ek2DvhrYgIXHyyPP9M6OZP8sAggWCFX2xLVBJSY5RhQoMISog5owX-3vZ6iZxP1tBCFkeBfVJdhrCNoIlJOhhdoIQIZjXcJX9WHsXws9v370OJoxyUBqMDqh5dMEMGkgvGzPEuNXADECCfrKjaf30-Y5mBJuplwPYedfP2rqoNgoobS2wqUjQVqtRt6BzHvzZqHV756fGKDO8BKbfWaPkaNwQDqxyfex--ABqo3s3brSXu_lR9qCTNujHy3uWfXpz8XF9mV99ePtufX6VKwIZzzFVTCLOathWRJWNbDFXEBHECEUd5pSrsmtZLZu26oiuOoVigqAKE44po-VZlh_rhmu9mxqx86aXfhZOGrF8fYmRFoRTSnnk2T_5uJz2VvRbiHjF4-mi8vlRGbGvkw6j6E1IG5SDdlMQDCEGEU4jPf0L3LrJD3ELsVZd1WVN6wjVR0il63rd3UyCoEgOEluRjCKSUURykDg4SOyj9MlSf2p63d4KF8tE4NkCyKCk7Xw8pQl3OMxhmbBXR-zaWD3_d3_x-v1lispfViHpag</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198483868</pqid></control><display><type>article</type><title>Cross‐resistance to cytosine arabinoside in a multidrug‐resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Månsson, Emma ; Paul, Astrid ; Löfgren, Christina ; Ullberg, Karin ; Paul, Christer ; Eriksson, Staffan ; Albertioni, Freidoun</creator><creatorcontrib>Månsson, Emma ; Paul, Astrid ; Löfgren, Christina ; Ullberg, Karin ; Paul, Christer ; Eriksson, Staffan ; Albertioni, Freidoun</creatorcontrib><description>The pyrimidine analogue cytosine arabinoside (AraC) is one of the most effective drugs used in the treatment of acute leukaemia. Overexpression of the multidrug resistance (MDR‐1) gene and its product, P‐glycoprotein (P‐gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. This resistance can be reversed by cyclosporine analogues or verapamil (ver). We investigated the in vitro cross‐resistance to AraC in a doxorubicin‐resistant HL60 cell line, with an elevated expression of the MDR‐1 gene. The resistant clone showed an eightfold increased resistance to AraC and a two‐ to fourfold resistance to the other analogues, as measured by cytotoxicity test. There was no significant increase in the activity of 5′‐nucleotidase or in the amount of deoxyribonucleotide pools between cell lines. We could, however, detect a reduction in deoxycytidine kinase (dCK) activity (30%, P = 0·021, using deoxycytidine as substrate) and the level of AraC triphosphates was significantly reduced in the resistant cells (70%, P = 0·009). When the cells were exposed to cyclosporin A (CsA) or the cyclosporine analogue PSC 833 (PSC) in combination with AraC, there was more extensive apoptosis, as measured by formation of oligonucleosomal DNA fragmentation and caspase‐3‐like activity, than with exposure to AraC alone. We also found an increased retention of AraC in the resistant cells when incubated with AraC in combination with CsA. Ver in combination with AraC, failed to increase apoptosis for the resistant cell line. Our data suggests that the resistance to AraC for the P‐gp‐expressing cells is a result of a reduction of dCK activity and an increase in efflux, the latter possibly depending on P‐gp. A combination of CsA or PSC with AraC may improve the effect of AraC in vivo.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.2001.02979.x</identifier><identifier>PMID: 11552980</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Antineoplastic agents ; Apoptosis - drug effects ; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism ; Biological and medical sciences ; Chemotherapy ; Cyclosporine - pharmacology ; cyclosporinee A ; Cyclosporins - pharmacology ; Cytarabine ; cytosine arabinoside ; deoxycytidine kinase ; Deoxycytidine Kinase - metabolism ; DNA Fragmentation ; Doxorubicin ; Drug Resistance, Multiple ; Flow Cytometry ; Fluoresceins - metabolism ; Hematology ; HL-60 Cells - metabolism ; Humans ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukemia, Promyelocytic, Acute - metabolism ; Medical sciences ; Medicin och hälsovetenskap ; Pharmacology. Drug treatments ; PSC 833 ; P‐glycoprotein</subject><ispartof>British journal of haematology, 2001-09, Vol.114 (3), p.557-565</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Sep 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763</citedby><cites>FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1129030$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11552980$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1949979$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Månsson, Emma</creatorcontrib><creatorcontrib>Paul, Astrid</creatorcontrib><creatorcontrib>Löfgren, Christina</creatorcontrib><creatorcontrib>Ullberg, Karin</creatorcontrib><creatorcontrib>Paul, Christer</creatorcontrib><creatorcontrib>Eriksson, Staffan</creatorcontrib><creatorcontrib>Albertioni, Freidoun</creatorcontrib><title>Cross‐resistance to cytosine arabinoside in a multidrug‐resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>The pyrimidine analogue cytosine arabinoside (AraC) is one of the most effective drugs used in the treatment of acute leukaemia. Overexpression of the multidrug resistance (MDR‐1) gene and its product, P‐glycoprotein (P‐gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. This resistance can be reversed by cyclosporine analogues or verapamil (ver). We investigated the in vitro cross‐resistance to AraC in a doxorubicin‐resistant HL60 cell line, with an elevated expression of the MDR‐1 gene. The resistant clone showed an eightfold increased resistance to AraC and a two‐ to fourfold resistance to the other analogues, as measured by cytotoxicity test. There was no significant increase in the activity of 5′‐nucleotidase or in the amount of deoxyribonucleotide pools between cell lines. We could, however, detect a reduction in deoxycytidine kinase (dCK) activity (30%, P = 0·021, using deoxycytidine as substrate) and the level of AraC triphosphates was significantly reduced in the resistant cells (70%, P = 0·009). When the cells were exposed to cyclosporin A (CsA) or the cyclosporine analogue PSC 833 (PSC) in combination with AraC, there was more extensive apoptosis, as measured by formation of oligonucleosomal DNA fragmentation and caspase‐3‐like activity, than with exposure to AraC alone. We also found an increased retention of AraC in the resistant cells when incubated with AraC in combination with CsA. Ver in combination with AraC, failed to increase apoptosis for the resistant cell line. Our data suggests that the resistance to AraC for the P‐gp‐expressing cells is a result of a reduction of dCK activity and an increase in efflux, the latter possibly depending on P‐gp. A combination of CsA or PSC with AraC may improve the effect of AraC in vivo.</description><subject>Antineoplastic agents</subject><subject>Apoptosis - drug effects</subject><subject>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Cyclosporine - pharmacology</subject><subject>cyclosporinee A</subject><subject>Cyclosporins - pharmacology</subject><subject>Cytarabine</subject><subject>cytosine arabinoside</subject><subject>deoxycytidine kinase</subject><subject>Deoxycytidine Kinase - metabolism</subject><subject>DNA Fragmentation</subject><subject>Doxorubicin</subject><subject>Drug Resistance, Multiple</subject><subject>Flow Cytometry</subject><subject>Fluoresceins - metabolism</subject><subject>Hematology</subject><subject>HL-60 Cells - metabolism</subject><subject>Humans</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukemia, Promyelocytic, Acute - metabolism</subject><subject>Medical sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Pharmacology. Drug treatments</subject><subject>PSC 833</subject><subject>P‐glycoprotein</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqNksFu1DAQhiMEotvCKyALIW4JthPbMRKHsioUVIkLnC3HcVgvTrzYibq58Qi8DC_Ek2DvhrYgIXHyyPP9M6OZP8sAggWCFX2xLVBJSY5RhQoMISog5owX-3vZ6iZxP1tBCFkeBfVJdhrCNoIlJOhhdoIQIZjXcJX9WHsXws9v370OJoxyUBqMDqh5dMEMGkgvGzPEuNXADECCfrKjaf30-Y5mBJuplwPYedfP2rqoNgoobS2wqUjQVqtRt6BzHvzZqHV756fGKDO8BKbfWaPkaNwQDqxyfex--ABqo3s3brSXu_lR9qCTNujHy3uWfXpz8XF9mV99ePtufX6VKwIZzzFVTCLOathWRJWNbDFXEBHECEUd5pSrsmtZLZu26oiuOoVigqAKE44po-VZlh_rhmu9mxqx86aXfhZOGrF8fYmRFoRTSnnk2T_5uJz2VvRbiHjF4-mi8vlRGbGvkw6j6E1IG5SDdlMQDCEGEU4jPf0L3LrJD3ELsVZd1WVN6wjVR0il63rd3UyCoEgOEluRjCKSUURykDg4SOyj9MlSf2p63d4KF8tE4NkCyKCk7Xw8pQl3OMxhmbBXR-zaWD3_d3_x-v1lispfViHpag</recordid><startdate>200109</startdate><enddate>200109</enddate><creator>Månsson, Emma</creator><creator>Paul, Astrid</creator><creator>Löfgren, Christina</creator><creator>Ullberg, Karin</creator><creator>Paul, Christer</creator><creator>Eriksson, Staffan</creator><creator>Albertioni, Freidoun</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>200109</creationdate><title>Cross‐resistance to cytosine arabinoside in a multidrug‐resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy</title><author>Månsson, Emma ; Paul, Astrid ; Löfgren, Christina ; Ullberg, Karin ; Paul, Christer ; Eriksson, Staffan ; Albertioni, Freidoun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antineoplastic agents</topic><topic>Apoptosis - drug effects</topic><topic>ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Cyclosporine - pharmacology</topic><topic>cyclosporinee A</topic><topic>Cyclosporins - pharmacology</topic><topic>Cytarabine</topic><topic>cytosine arabinoside</topic><topic>deoxycytidine kinase</topic><topic>Deoxycytidine Kinase - metabolism</topic><topic>DNA Fragmentation</topic><topic>Doxorubicin</topic><topic>Drug Resistance, Multiple</topic><topic>Flow Cytometry</topic><topic>Fluoresceins - metabolism</topic><topic>Hematology</topic><topic>HL-60 Cells - metabolism</topic><topic>Humans</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukemia, Promyelocytic, Acute - metabolism</topic><topic>Medical sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Pharmacology. Drug treatments</topic><topic>PSC 833</topic><topic>P‐glycoprotein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Månsson, Emma</creatorcontrib><creatorcontrib>Paul, Astrid</creatorcontrib><creatorcontrib>Löfgren, Christina</creatorcontrib><creatorcontrib>Ullberg, Karin</creatorcontrib><creatorcontrib>Paul, Christer</creatorcontrib><creatorcontrib>Eriksson, Staffan</creatorcontrib><creatorcontrib>Albertioni, Freidoun</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Månsson, Emma</au><au>Paul, Astrid</au><au>Löfgren, Christina</au><au>Ullberg, Karin</au><au>Paul, Christer</au><au>Eriksson, Staffan</au><au>Albertioni, Freidoun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cross‐resistance to cytosine arabinoside in a multidrug‐resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2001-09</date><risdate>2001</risdate><volume>114</volume><issue>3</issue><spage>557</spage><epage>565</epage><pages>557-565</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>The pyrimidine analogue cytosine arabinoside (AraC) is one of the most effective drugs used in the treatment of acute leukaemia. Overexpression of the multidrug resistance (MDR‐1) gene and its product, P‐glycoprotein (P‐gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. This resistance can be reversed by cyclosporine analogues or verapamil (ver). We investigated the in vitro cross‐resistance to AraC in a doxorubicin‐resistant HL60 cell line, with an elevated expression of the MDR‐1 gene. The resistant clone showed an eightfold increased resistance to AraC and a two‐ to fourfold resistance to the other analogues, as measured by cytotoxicity test. There was no significant increase in the activity of 5′‐nucleotidase or in the amount of deoxyribonucleotide pools between cell lines. We could, however, detect a reduction in deoxycytidine kinase (dCK) activity (30%, P = 0·021, using deoxycytidine as substrate) and the level of AraC triphosphates was significantly reduced in the resistant cells (70%, P = 0·009). When the cells were exposed to cyclosporin A (CsA) or the cyclosporine analogue PSC 833 (PSC) in combination with AraC, there was more extensive apoptosis, as measured by formation of oligonucleosomal DNA fragmentation and caspase‐3‐like activity, than with exposure to AraC alone. We also found an increased retention of AraC in the resistant cells when incubated with AraC in combination with CsA. Ver in combination with AraC, failed to increase apoptosis for the resistant cell line. Our data suggests that the resistance to AraC for the P‐gp‐expressing cells is a result of a reduction of dCK activity and an increase in efflux, the latter possibly depending on P‐gp. A combination of CsA or PSC with AraC may improve the effect of AraC in vivo.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11552980</pmid><doi>10.1046/j.1365-2141.2001.02979.x</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1048 |
ispartof | British journal of haematology, 2001-09, Vol.114 (3), p.557-565 |
issn | 0007-1048 1365-2141 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_596669 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Antineoplastic agents Apoptosis - drug effects ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Biological and medical sciences Chemotherapy Cyclosporine - pharmacology cyclosporinee A Cyclosporins - pharmacology Cytarabine cytosine arabinoside deoxycytidine kinase Deoxycytidine Kinase - metabolism DNA Fragmentation Doxorubicin Drug Resistance, Multiple Flow Cytometry Fluoresceins - metabolism Hematology HL-60 Cells - metabolism Humans Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - metabolism Medical sciences Medicin och hälsovetenskap Pharmacology. Drug treatments PSC 833 P‐glycoprotein |
title | Cross‐resistance to cytosine arabinoside in a multidrug‐resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A05%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cross%E2%80%90resistance%20to%20cytosine%20arabinoside%20in%20a%20multidrug%E2%80%90resistant%20human%20promyelocytic%20cell%20line%20selected%20for%20resistance%20to%20doxorubicin:%20implications%20for%20combination%20chemotherapy&rft.jtitle=British%20journal%20of%20haematology&rft.au=M%C3%A5nsson,%20Emma&rft.date=2001-09&rft.volume=114&rft.issue=3&rft.spage=557&rft.epage=565&rft.pages=557-565&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.2001.02979.x&rft_dat=%3Cproquest_swepu%3E71170126%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5079-26c7a19780d45c3bad29c01517561f2969c3fd78abd4f5e4fc156151425926763%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198483868&rft_id=info:pmid/11552980&rfr_iscdi=true |